We are thrilled to announce that AbbVie Ventures has launched the 2023 AbbVie Innovation Midwest (AIM) Awards, one of AbbVie’s signature events aimed at supporting the growth of the biopharma industry. Through the AIM Awards, up to two early-stage biotech companies will be selected to receive seed funding under standard industry terms, providing them with the necessary financial support to bring their ideas to life.
The AIM Awards are part of AbbVie’s commitment to promoting the formation of new biotech companies and a thriving biopharma ecosystem in the Midwest region. As an iBIO member, AbbVie is dedicated to advancing biopharmaceutical innovation and enhancing the quality of life for patients around the world.
We encourage all early-stage biotech companies in the Midwest region to consider applying for the AIM Awards by the July 7th deadline. This is an incredible opportunity for startups to access vital funding and resources that can help take their innovations to the next level.
For more information on the AIM Awards, including application requirements, please visit the AbbVie Ventures website. We look forward to supporting the next generation of biotech leaders and helping to build a brighter future for the biopharma industry in the Midwest.